A critical supplier to the global medical diagnostics industry; @Microbix CEO Cameron Groome presented and attended 1x1 meetings across Canada this week.
🔵🔴 Discussion highlights:
- Q1 FY2026 revenue up 13% sequentially
- $9.1M cash position
- Targeting return to quarterly profitability by late FY2026
With ~100 global diagnostic programs, expanding QAPs™ growth, and the fully funded Kinlytic royalty opportunity, #Microbix combines durable core cash flows with asymmetric upside.
$MBX $MBXBF
Canada’s life sciences sector is at a turning point. With CUSMA renewal ahead, Microbix CEO Cameron Groome argues that Canada must strengthen its scientific and manufacturing capacity — not just rely on tariff protection.
Read full article on out LinkedIn!
🔬 Microbix is heading to the 16th Annual #NMG Fall Meeting in Toronto, November 10–12, 2025!
📍 Find us at Table #118
We’re advancing molecular diagnostics to help labs strengthen validation, consistency, and global health outcomes. See you at NMG 2025!
🧬 Microbix is headed to #NMG in Toronto!
Join us to explore how our reference materials and diagnostic solutions are advancing accuracy, validation, and global public health.
📍Event Details -November 11–12: Peter Gilgan Centre for Research and Learning
#Toronto#eventpick
💚 World Mental Health Day 2025 💚
At Microbix, we believe mental health is just as vital as physical health, in the lab, the office, and beyond. Behind every innovation are people who thrive when they feel supported, heard, and valued.
#WorldMentalHealthDay#WellbeingAtWork
@DrJawaadArif@DrJawaadArif Thank you! We’re proud to support labs in improving diagnostic accuracy and ultimately contributing to public health outcomes.
🌍 When precision meets preparedness, real change happens. Proud to partner with API to support labs in detecting and responding to emerging threats like H5N1.
With decades of expertise, Microbix continues setting the standard for quality and innovation in diagnostics.
#H5N1
Fungal infections affect more than 1 billion people every year, yet diagnostics still face gaps.
The QUANTDx™ Fungal Panel, with over 20 products, provides quantified, traceable, and concentrated reference materials.
Explore: https://t.co/J261uGqxaL
#HealthcareForAll
QUANTDx™ is gaining strong traction in the diagnostics community. The demand for reliable, fully quantified reference materials is clear , and we’re proud to deliver. At Microbix, we’re committed to empowering partners to advance healthcare outcomes worldwide. 🌍
#Healthcare
We’re thrilled to have launched QUANTDx™, our new product line designed to accelerate and optimize assay development and QC programs.
With 80+ products across 6 panels, your team can access the reliable materials needed to streamline testing.
👉 https://t.co/J261uGqxaL
Assay developers need more than +/– results, they need precision. 🔬
That’s why we built QUANTDx™ Reference Materials: traceable, consistent, and quantified tools to benchmark assays & support validation.
Explore panels 👉 https://t.co/J261uGpZld
#diagnostics